Arcturus Therapeutics Presents ARCT-810 Data at 2026 Symposium

What Happened Arcturus Therapeutics Holdings, Inc. (ARCT) filed a Form 8-K on August 25, 2026 disclosing a Regulation FD presentation. The company will present a poster titled “Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency” at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, Finland. The presentation is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: August 25, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Presentation title: “Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency.”
• Event: 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Helsinki, Finland.
• Company note: Additional data and the regulatory plan for the ARCT-810 program are expected to be communicated later this quarter.

Why It Matters This filing signals ongoing clinical and regulatory activity for ARCT-810, Arcturus’s mRNA therapy candidate for ornithine transcarbamylase (OTC) deficiency. Public presentation of biochemical and dietary intake data can be an important near-term informational catalyst; investors should watch for the additional data and the company’s regulatory plan due later this quarter, which could affect perceptions of the program’s progress and timing.